华蟾素注射液和艾迪注射液治疗脾气虚型晚期大肠癌的对照研究  

Comparative study of treatment of advanced colorectal cancer with Huachansu Injection and AD Injection

作　　者：祝利民[1] 沈克平[1] 周浩[1] 潘传芳[1] 卢艳琳 

机构地区：[1]上海中医药大学附属龙华医院肿瘤科,上海200032

出　　处：《上海交通大学学报（医学版）》2013年第12期1625-1629,1633,共6页Journal of Shanghai Jiao tong University:Medical Science

基　　金：上海市教委预算内科研项目(2012JW33)~~

摘　　要：目的探讨华蟾素注射液和艾迪注射液对晚期大肠癌的治疗作用。方法将60例晚期大肠癌患者随机分为两组,华蟾素组(n=30)采用华蟾素注射液加基础治疗,艾迪组(n=30)采用艾迪注射液加基础治疗,每个疗程10 d,休息2周后继续下一疗程,共4个疗程。比较两组患者的中医证候和生存质量,观察外周血NK和T细胞亚群分布及血清肿瘤血清标志物癌胚抗原(CEA)和糖类抗原199(CA199)水平的变化。结果艾迪组患者治疗后在腹痛喜热喜按、神疲乏力、面色萎黄、舌淡胖苔白等症状上较治疗前以及华蟾素组治疗后均明显改善,差异有统计学意义(P<0.05)。艾迪组证候改善率和总有效率分别为46.67%和76.67%,均明显优于华蟾素组的23.33%和63.33%,差异有统计学意义(P<0.05)。在改善免疫功能上,治疗后两组患者的免疫学指标CD3、CD4、NK细胞百分比和CD4/CD 8均明显提高,与治疗前比较差异有统计学意义(P<0.05);但治疗后两组间比较差异均无统计学意义(P>0.05)。在血清肿瘤标志物CEA及CA199的改善上,华蟾素组均明显优于艾迪组(P<0.05)。结论针对晚期脾气虚的大肠癌患者,华蟾素注射液和艾迪注射液均有较好疗效,艾迪注射液在改善患者中医证候及生存质量上有优势,华蟾素注射液则能有效改善肿瘤血清标志物CEA及CA199的表达,其内在机制有待进一步探讨。Objective To study the effect of huachansu （HCS） injection and AD injection on treatment of advanced coloreetal cancer. Methods Sixty patients with advanced colorectal cancer were randomly assigned into 2 groups. The HCS group （30 cases） was treated with HCS injection and basal therapy; and the AD group （30 eases） was treated with AD injection and basal therapy. All the patients received 4 treatment courses which were of 10 d and 2 weeks off as one course. The traditional Chinese medicine syndrome, quality of survival, NK and T cells, serum CEA and CA199 levels were observed. Results In AD group, patients got remarkable improvement in joy for hot and pressing, fatigue, sallow complexion, and pale tongue with fat tongue body and white fur after treatment, and there were significant differences compared to HCS group （P 〈 O. 05）. The improvement rate and total effective rate were 46.67% and 76.67% in AD group, which were better than 23.33% and 63. 33% in HCS group （P 〈 0.05）. For improvement of immune function, the immunological indexes of CD3, CD4, the percentage of NK ceils and CD4/CD8 of patients in two groups improved markedly in comparison to before treatment （ P 〈 0.05）, but there were no statistical differences between two groups （ P 〉 0.05）. However, the of serum tumor markers of CEA and CA199 had better improvement in HCS group （P 〈 0.05）. Conclusion In treatment on advanced spleen-qi deficiency colorectal cancer patients, HCS injection and AD injection had good curative effect. AD injection improved patient＇s syndromes and quality of life, and HCS injection improve the expression of serum tumor markers CEA and CA199, whose internal mechanism needs further research.

关 键 词：华蟾素注射液 艾迪注射液 晚期大肠癌 

分 类 号：R735.34[医药卫生—肿瘤] R285.6[医药卫生—临床医学]